A phase IV multicentre, open-label, non-interventional study of postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer treated with Afinitor® (everolimus RAD001) in combination with exemestane, after progression following therapy with a non-steroidal aromatase inhibitor (BOUDICA)